AlphAIAlphAI — Financial news for AI agents
sharechat.co.nzAUG 212 min read$FPH

FPH provides first half FY27 guidance, updates FY27 outlook

Fisher & Paykel Healthcare (FPH) provided first-half FY27 guidance, expecting $1.24B revenue and $280M net profit, up 14% and 24% respectively. Full-year outlook raised to $2.47B-$2.57B revenue and $525M-$565M net profit, including $23M in tariff refunds. Growth driven by strong demand and clinical practice changes.

Original reporting
sharechat.co.nz
Published Aug 21, 2026, 2:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 3:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$FPH
Bullish
high confidence
Mentioned
$FPH
Relevance
8/10
AlphAI data visualization · based on sharechat.co.nz
Decision brief

The 30-second read

$FPHBullishMed
01

Why it matters

Guidance suggests a stronger operating environment and could lift the stock.

02

Market read

First‑hand guidance update provides fresh material for traders.

03

What to watch

Potential currency fluctuations and regulatory changes could affect actual results.

Relevance 8/10Novelty 8/10Timing: released on Aug 21 2026

Background

Fisher & Paykel Healthcare is a New Zealand‑based manufacturer of respiratory‑care devices.

Company-level read

Ticker impact

$FPHBullishHigh confidence
Context

Fisher & Paykel Healthcare released FY27 first‑half and full‑year revenue and profit guidance, updating its outlook.

Expected impact

Potential upside as investors price in higher earnings outlook.

Evidence & confidence

Guidance numbers are materially above prior guidance and reflect a 14% revenue growth and 24% profit growth YoY.

Market effects

Sector

Positive signal for the medical‑device and respiratory‑care sector.

Regional

Supports New Zealand‑listed health‑care stocks.

Global

May influence global investors tracking healthcare earnings trends.

Counterpoint

What could challenge this read

If margin improvements stall, the guidance could be overly optimistic.

Key entities

  • Executive
    Lewis Gradon

    Managing Director and CEO of Fisher & Paykel Healthcare.

Read at source← All news

Related articles

SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
AUG 21
$FPHMedAI 8/10

Market quiet but earnings showing positive signs

Fisher & Paykel Healthcare upgraded its 2027 guidance, citing strong hospital product sales. Revenue and net profit forecasts increased, with first-half revenue expected at $1.24B and net profit at $280M. The stock closed at $43.52. On Wall Street, the Dow fell 1.32% as bond yields rose and Walmart missed earnings. In NZ, several companies reported earnings, including South Port NZ and Seeka.

nzherald.co.nz2 min
AUG 17
$FPHMed

FPH turns down KKR bid for First Gen stake over valuation

First Philippine Holdings (FPH) rejected KKR’s non-binding bid to buy an additional 8.43% stake in First Gen and then tender for First Gen’s public float at P36/share, saying it undervalues First Gen. FPH owns 67.84% of First Gen; KKR has 19.9% economic interest. The deal would have supported a delisting. First Gen also weighs a $5B offer from BREN for EDC.

bworldonline.com5 min
AUG 17
$FPHMedAI 8/10

First Holdings thumbs down KKR offer

First Philippine Holdings (FPH) rejected KKR’s non-binding proposal to buy part of FPH’s stake in First Gen Corp. and to launch a voluntary tender offer for First Gen’s public float at PHP 35 per share. FPH said the offer does not reflect First Gen’s true value. KKR holds about 19.9% economic interest and plans delisting via the tender offer.

philstar.com3 min
AUG 17
$FPHMed

First Phil Holdings rejects KKR bid for First Gen stake

First Philippine Holdings (FPH) said it rejected KKR’s non-binding bid to buy FPH’s 8.43% stake in First Gen and launch a voluntary tender offer for First Gen’s 11.67% public float at P35 per share. FPH said the proposal does not reflect First Gen’s true value and ended its participation. FPH shares fell P1 to P102; First Gen fell P3.50 to P27.20.

manilatimes.net2 min
AUG 14
$KKRMed

Making sense of US firm KKR’s offer on Lopez family’s First Gen

KKR emailed First Philippine Holdings (FPH) and First Gen Corp. on July 10 with a three-step plan, disclosed in an Aug. 13 letter to the PSE. KKR would buy 8.43% of First Gen from FPH, then buy the 11.67% public float, and seek delisting. KKR says any change-of-control deal would trigger a mandatory tender offer and a control premium at least 30% above its offer price (about P46 vs ~P35).

rappler.com9 min